Foto av Thomas Mandl

Thomas Mandl

Knuten till universitetet, Docent i Reumatologi

Personlig profil

Forskning

CURRICULUM VITAE

Name: Thomas Mandl

Address: Collins väg 53, SE-236 33 Höllviken, Sweden

Mobile phone: +46/730/795322

E-mail: [email protected]

EDUCATION:         

  • Doctor’s examination: 15 January 1998

  • MD: 28 February 2001

  • Specialist in Rheumatology: 15 July 2007

  • PhD: ‘Autonomic dysfunction in primary Sjögren’s syndrome’ 5 June 2008

  • Specialist in Internal Medicine: 1 September 2009

  • Management education September 2008-September 2009

  • Associate Professor Rheumatology at Lund University 3 April 2012

RESEARCH:

  • Original publications in international journals: 65

  • Text book chapters: 8

  • H-index (2022): 29
  • Review assignments for the following international journals: Annals of Rheumatic Diseases, Arthritis Care and Research, Arthritis and Rheumatology, Journal of Rheumatology, New England Journal of Medicine, Rheumatology Oxford, and Scandinavian Journal of Rheumatology.

  • Ongoing research projects:

  • Malmö primary Sjögren’s syndrome (pSS) registry (MSSR)

  • Member of Scandinavian DISSECT Sjögren’s Syndrome consortium

  • Previous research projects:

    • Member of the EULAR Sjögren’s Syndrome Task force

    • Member of International BIG-DATA-Sjögren’s Syndrome consortium

WORK EXPERIENCE:

  • 1998-1999 Physician in Internal Medicine, Malmö University Hospital

  • 1999-2001 Internship, Länssjukhuset Ryhov, Jönköping

  • 2001-2007 Resident in Rheumatology, Malmö University Hospital

  • 2007-2009 Resident in Internal Medicine, Malmö University Hospital

  • 2009-2012 Specialist Rheumatology & Internal Medicine, Skåne Uni Hospital

  • 2012-2018 Sr Consultant Rheumatology & Internal Medicine, Skåne Uni Hospital

  • 2018- 2020 Medical Advisor Rheumatology, Novartis Sweden AB, Sweden

    • Supporting country medical affairs strategy in line with the global strategy, country insights and market conditions, and secure implementation of planned Medical Affairs activities. Coordinating scientific meeting, symposia, congresses, and continuous medical education. Providing medical/scientific input into the development and execution of clinical trial or clinical research related activities. Coordinating review and approval of medical materials. Ensuring medical insights are provided to cross functional groups. Being responsible for risk identification and assessment, and mitigation planning.

  • 2021- 2022 Medical Lead Rheumatology, Novartis Sweden AB, Sweden

    • Supporting country medical affairs strategy in line with the global strategy, country insights and market conditions, and secure implementation of planned Medical Affairs activities. Coordinating scientific meeting, symposia, congresses, and continuous medical education. Providing medical/scientific input into the development and execution of clinical trial or clinical research related activities. Coordinating review and approval of medical materials. Ensuring medical insights are provided to cross functional groups. Being responsible for risk identification and assessment, and mitigation planning.

  • 2021- 2022 Global Medical Affairs Rotation, Novartis

    • Supporting the development of the Integrated Evidence Generation Plan for Sjögren’s disease across compounds, ensuring a continuous alignment cross-function and cross-compound on the Sjögren’s disease area pain points and the evidences needed to address the gaps.

  • 2022-        Medical Solution Lead Rheumatology, UCB Sweden AB

ADMINISTRATIVE EXPERIENCE:

  • Director of studies Rheumatology, Swedish Southern Healthcare Region 2010-2013

  • Treasurer, Board of Directors, The Swedish Association of Rheumatology 2014-2016

  • Unit responsible physician, Rheumatology, Skåne Uni Hospital, Malmö 2013-2018

PEDAGOGIC EXPERIENCE:

  • Clinical Assistant Internal Medicine and Rheumatology, September 2001-June 2002

  • Director of studies Rheumatology, Swedish Southern Healthcare Region 2010-2013

  • Lecturer in Rheumatology (Sjögren’s syndrome, rheumatoid arthritis, spondylarthritis, psoriatic arthritis, osteoarthritis, rheumatologic pharmacotherapy and pain physiology) for AbbVie, Biogen, BMS, Celgene, MSD, Novartis, Pfizer, Roche, UCB, 2002-2018.

SUPERVISION:

  • Assistant supervisor for PhD student Oskar Hammar 2009-2013, PhD 1 March 2013.

  • Main supervisor for PhD student Peter Olsson 2017-2019, PhD 20 Sept 2019.

  • Main supervisor for PhD student Anna M Nilsson 2013-2019, PhD 29 Nov 2019.

  • Assistant supervisor for PhD student Anna Eberhard 2020-

INVITED LECTURER:

  • Autonomic neuropathy in pSS, ACR 2010, Atlanta, USA, 9 Nov 2010.

  • Pulmonary manifestations in pSS, ACR 2015, San Francisco, USA, 9 Nov 2015.

  • New drugs and evaluation of Sjögren’s syndrome treatment, Argentinian Society of Rheumatology, Buenos Aires-Virtually, Argentina, 13 Oct 2022

GRANTS/AWARDS:

  • Swedish Abbott grant in Rheumatology 2011 – 50.000SEK.

  • ALF-YF, first period, 2012-2014 – 2.400.000SEK.

  • ALF-YF, second period, 2015-2017 – 2.400.000SEK.

  • ALF-YF, third period, 2018-2020 – 675.000SEK.

PhD OPPONENT AND DISSERTATION BOARD:

  • PhD opponent:

    • Marika Kvarnström, Karolinska Institute, Stockholm 9 May 2014.

    • Lilian Vasaitis, Uppsala University, Uppsala 10 June 2017.

  • Dissertation board:

    • Emma Haglund, Lund University Lund 8 Nov 2013.

    • Caroline Feldthusen, Gothenburg University, Göteborg 18 Sept 2015.

    • Hans Lindgren, Lund University, Helsingborg 22 Apr 2016.

    • Vijay Balasingh, Karolinska Institute, Stockholm 7 Sept 2017.

    • Karina Malm, Lund University, Lund 17 Nov 2017.

    • Elisabeth Mogard, Lund University, Lund 12 Oct 2018.

ADDITIONAL INFORMATION:

  • Born 6 February 1973

  • Austrian citizen

  • One daughter Helene, born 2004.

  • Languages:

    • Swedish - Native or bilingual proficiency

    • English - Full professional proficiency

    • German - Limited working proficiency

    • French - Elementary proficiency

PRESENT APPOINTMENT:

  • Medical Solution Lead Rheumatology, UCB Sweden AB, Sweden

  • Associate Professor Rheumatology, Lund University, Lund, Sweden

Expertis relaterad till FN:s globala mål

2015 godkände FN:s medlemsstater 17 Globala mål för en hållbar utveckling, för att utrota fattigdomen, skydda planeten och garantera välstånd för alla. Den här personens arbete relaterar till följande Globala mål:

  • SDG 3 – God hälsa och välbefinnande

Fingeravtryck

Utforska forskningsämnen där Thomas Mandl är aktiv. Dessa ämnesetiketter kommer från personens arbeten. Tillsammans bildar de ett unikt fingeravtryck.
  • 1 Liknande profiler

Samarbeten under de senaste fem åren

Externa samarbeten med länder/områden de senaste 5 åren